美托洛尔与曲美他嗪治疗老年冠心病心力衰竭的疗效及对患者心功能、心肌重塑和炎症因子的影响

发布时间：2018-05-18 01:38

本文选题：美托洛尔 + 曲美他嗪　；参考：《中国老年学杂志》2017年01期

【摘要】：目的探讨美托洛尔与曲美他嗪联合治疗老年冠心病心力衰竭的临床疗效及对患者心功能、心肌重塑和炎症因子的影响。方法将入选的176例老年冠心病心力衰竭患者根据收治顺序单双号分为观察组和对照组,每组88例。两组患者均给予常规对症治疗,在此基础上,观察组患者采用美托洛尔与曲美他嗪联合治疗。治疗6个月后对比观察两组临床疗效、不良反应以及生命体征、心功能、心肌重塑和炎症因子等指标变化情况。结果观察组治疗后总有效率(94.32%)显著优于对照组(85.23%)(P0.05);两组患者治疗后的HR、SBP、DBP、LVEDD、LVESD、IL-6、TNF-α和hs-CRP均较治疗前显著降低(P0.05),且观察组降低更明显(P0.05);与治疗前比较,两组治疗后LVEF和6MWT显著升高(P0.05),且观察组治疗后LVEF和6MWT显著高于对照组治疗后(P0.05);在治疗期间两组均未发生明显不良反应。结论美托洛尔联合曲美他嗪对于老年冠心病心力衰竭患者治疗效果优良,能降低患者心肌重塑风险,降低炎症反应,有效改善患者生命体征、心功能,且安全性良好,值得临床积极借鉴。
[Abstract]:Objective to investigate the effect of metoprolol combined with trimetazidine on heart function, myocardial remodeling and inflammatory factors in elderly patients with coronary heart disease. Methods 176 elderly patients with heart failure were divided into observation group (n = 88) and control group (n = 88). Two groups of patients were treated with routine therapy. On this basis, the patients in the observation group were treated with metoprolol combined with trimetazidine. After 6 months of treatment, the changes of clinical efficacy, adverse reactions, vital signs, cardiac function, myocardial remodeling and inflammatory factors were compared between the two groups. Results the total effective rate after treatment in the observation group was significantly higher than that in the control group, which was 85.230.The HRT SBP of the two groups after treatment was significantly lower than that of the control group, and the levels of IL-6, TNF- 伪 and hs-CRP in the two groups were significantly lower than those before the treatment, and the decrease in the observation group was more obvious than that in the control group, and compared with that before treatment, there was no significant difference between the two groups. LVEF and 6MWT increased significantly after treatment in both groups, and LVEF and 6MWT in the observation group were significantly higher than those in the control group after treatment, and no significant adverse reactions occurred in both groups during the treatment period. Conclusion Metoprolol combined with trimetazidine is effective in the treatment of elderly patients with heart failure. It can reduce the risk of myocardial remodeling, reduce inflammatory reaction, improve the vital signs and cardiac function of the patients, and the safety is good. It is worthy of clinical active reference.
【作者单位】：武汉科技大学医院内科;武汉科技大学医院心血管内科;武汉科技大学医院检验科;
【分类号】：R541.6;R541.4

【参考文献】